Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)

NCT06146725 is registered in ClinicalTrials.gov with Jasper Gerritsen as lead sponsor.

NCT NCT06146725
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06146725 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
Lead sponsor
Jasper Gerritsen
Phase
Observational
Overall status
Recruiting
Start date
January 1, 2023
Completion date
January 1, 2029
Enrollment
564 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma, glioblastoma multiforme, glioblastoma multiforme of brain, glioblastoma multiforme, adult, glioblastoma, idh-wildtype